Where Legend Biotech Stands With Analysts
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ:LEGN) has received mixed analyst ratings, with a majority being bullish. The average 12-month price target is $76.7, slightly up from the previous $76.00. The company has shown significant revenue growth but faces challenges with ROE and ROA.
September 27, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech has received a mix of bullish and somewhat bullish ratings from analysts, with an average price target of $76.7. The company has shown strong revenue growth but faces challenges with ROE and ROA.
The majority of analysts have a bullish outlook on Legend Biotech, with a slight increase in the average price target. The company's strong revenue growth supports a positive short-term outlook, despite challenges in ROE and ROA.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100